Hodgkin Lymphoma
Hodgkin Lymphoma
The latest news, research, and perspectives in Hodgkin lymphoma. Both types of Hodgkin lymphoma, classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma, affect the lymphatic system and advances in diagnosis and treatment have led to high cure rates.
Advertisement
Nirav Shah, MD, MSHPTransplantation & Cellular Therapy | April 11, 2025
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Stephen M/ Ansell, MD, PhDHodgkin Lymphoma | April 10, 2025
Stephen M. Ansell, MD, PhD, explains the importance of making an accurate diagnosis of Hodgkin lymphoma.
Melissa BadamoVideo Insights | April 9, 2025
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
Nichole TuckerAggressive B-Cell Lymphoma | April 9, 2025
United States District Judge Sean D. Jordan entered the final judgment to vacate a new FDA regulation regarding lab tests.
Melissa BadamoAcute Lymphoblastic Leukemia | April 8, 2025
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Melissa BadamoHodgkin Lymphoma | March 28, 2025
Andrew M. Evens, DO, MBA, MSc, shared practice-changing studies in Hodgkin lymphoma and what to expect in 2025.
Advertisement
Andrew MorenoHodgkin Lymphoma | March 24, 2025
A study found maximum tumor diameter and lack of radiotherapy with chemotherapy are independent risk factors for HL relapse.
Melissa BadamoHodgkin Lymphoma | March 21, 2025
FDG-PET response-guided salvage may identify which pediatric patients achieve excellent outcomes without transplant.
Andrew MorenoHodgkin Lymphoma | March 21, 2025
Challenges exist in translating individual patients' risk into risk groups for use in everyday practice or a trial's design.
Andrew MorenoHodgkin Lymphoma | March 21, 2025
A phase 2 study sought to determine if use of nivolumab instead of vinblastine in the test combination improved safety.
Melissa BadamoHodgkin Lymphoma | March 21, 2025
BrECADD showed better tolerability and efficacy than eBEACOPP for the treatment of advanced-stage classical Hodgkin lymphoma.
Melissa BadamoAcute Lymphoblastic Leukemia | March 14, 2025
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Greg Nowakowski, MDHodgkin Lymphoma | February 20, 2025
Dr. Nowakowski encourages physicians to refer patients to clinical trials exploring a novel mechanism for CNS lymphoma.
Greg Nowakowski, MDHodgkin Lymphoma | February 20, 2025
Resistance remains a challenge in central nervous system lymphoma, creating a need for novel therapeutic combinations.
Greg Nowakowski, MDHodgkin Lymphoma | February 20, 2025
The TakeAim study explores dual inhibition with BTK and IRAK4 inhibitors.
Greg Nowakowski, MDHodgkin Lymphoma | February 20, 2025
Grzegorz Nowakowski discusses the challenges and advances in central nervous system lymphoma treatment.
Blood Cancer TalksChronic Lymphocytic Leukemia | January 31, 2025
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
Andrew MorenoAcute Lymphoblastic Leukemia | January 10, 2025
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
Xu Ji, PhD, MSPHVideo Insights | January 3, 2025
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
Nichole TuckerHodgkin Lymphoma | December 10, 2024
Progression-free survival was extended with the use of nivolumab plus the AVD regimen in patients advanced cHL in SWOG S1826.
Advertisement
Advertisement